Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome
British Journal of Dermatology · 18.08.2026 · 195 (3) · 512-514
DOI: 10.1093/bjd/ljag211 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 23.07.2026. Verfasst von Saskia Ingen-Housz-Oro und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Henri-Mondor Hospital, AP-HP, Paris Est Créteil University, EpiDermE, Créteil, France. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Mogamulizumab (MOGA), an anti-CCR4 monoclonal antibody, improves progression-free survival (PFS) and overall survival in Sézary syndrome (SS). Recently, a multicentre retrospective study conducted by the French Cutaneous Lymphoma study group assessed PFS in 52 patients with SS (median age 73 years, 56% female sex, 75% stage IVA1) who discontinued MOGA for reasons other than disease progression (Moga-stop Study). We report data from an extended follow-up of this cohort, along with comparative PFS outcomes from a parallel SS cohort with continuous MOGA treatment until progression.
Autor:innen und Institutionen
- Department of Dermatology, Henri-Mondor Hospital, AP-HP, Paris Est Créteil University, EpiDermE, Créteil, France.
ORCID-Profile: Saskia Ingen-Housz-Oro, Marie Beylot-Barry
Zitieren
APA
Ingen-Housz-Oro, S., Amatore, F., El Aarbaoui, T., de Masson, A., Pham-Ledard, A., Dereure, O., Quereux, G., Faiz, S., de Vicq de Cumptich, M., Ram-Wolff, C., Janela-Lapert, R., Guenova, E., Lheure, C., Le Corre, Y., Adamski, H., Bonnet, N., Grange, F., Troin, L., Tzoumpa, S., …, & Beylot-Barry, M. (2026). Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome. British Journal of Dermatology, 195(3), 512-514. https://doi.org/10.1093/bjd/ljag211
Vancouver
Ingen-Housz-Oro S, Amatore F, El Aarbaoui T, de Masson A, Pham-Ledard A, Dereure O, et al. Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome. British Journal of Dermatology. 2026;195(3):512-514. doi:10.1093/bjd/ljag211
BibTeX
@article{IngenHouszOro2026,
author = {Ingen-Housz-Oro, Saskia and Amatore, Florent and El Aarbaoui, Tarik and de Masson, Adèle and Pham-Ledard, Anne and Dereure, Olivier and Quereux, Gaëlle and Faiz, Sarah and de Vicq de Cumptich, Marine and Ram-Wolff, Caroline and Janela-Lapert, Raphaël and Guenova, Emmanuella and Lheure, Coralie and Le Corre, Yannick and Adamski, Henri and Bonnet, Nathalie and Grange, Florent and Troin, Laura and Tzoumpa, Sofia and Bagot, Martine and Beylot-Barry, Marie},
title = {Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome},
journal = {British Journal of Dermatology},
year = {2026},
volume = {195},
number = {3},
pages = {512--514},
doi = {10.1093/bjd/ljag211}
}
EUVIMED